NuCana PLC
NCNA0.660USD
0.000
收盘 04/24, 16:00（美东）报价延迟15分钟
3.75M总市值
亏损市盈率 TTM
关于 NuCana PLC 公司
NuCana plc 是一家位于英国的临床阶段生物制药公司。该公司专注于通过应用其 ProTide 技术为癌症患者开发治疗效果。该公司的产品线包括 NUC-3373 和 NUC-7738。NUC-3373 是 5-氟尿嘧啶 (5-FU) 活性抗癌代谢物的 ProTide 转化。5-FU 是一种处方抗癌剂。NUC-3373 已在针对晚期实体瘤患者的 I 期临床试验中进行了评估，并且正在针对晚期结直肠癌患者进行 Ib/II 期临床试验。NUC-7738 是核苷类似物 3'-脱氧腺苷 (3'-Da) 的 ProTide 转化。该公司正在针对晚期实体瘤患者的 I/II 期临床试验中评估 NUC-7738。其产品线还包括 Acelari，它是核苷类似物吉西他滨的 ProTide 转化。该公司的子公司包括 NuCana, Inc.、NuCana Limited 和 NuCana BioMed Trustee Company Limited。
公司简介
公司代码NCNA
公司名称NuCana PLC
上市日期Sep 28, 2017
成立日期1997
CEOMr. Hugh S. Griffith
员工数量20
证券类型Depository Receipt
年结日Sep 28
公司地址Lochside House
城市EDINBURGH
上市交易所NASDAQ Capital Market Consolidated
国家United Kingdom
邮编EH12 9DT
电话4401313571111
网址https://www.nucana.com/
公司代码NCNA
上市日期Sep 28, 2017
成立日期1997
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Dr. David Harrison, M.D.
Dr. David Harrison, M.D.
Head - Translational Studies
Head - Translational Studies
--
--
Mr. Donald (Don) Munoz
Mr. Donald (Don) Munoz
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
10.60K
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
1.33K
+18.87%
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
749.00
+298.40%
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
22.00
--
Dr. Jeffrey D. Bloss, M.D.
Dr. Jeffrey D. Bloss, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 3月22日 周六
更新时间: 3月22日 周六
持股股东
股东类型
持股股东
股东统计
占比
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
持股股东
股东统计
占比
Sofinnova Investments, Inc
3.51%
Abingworth Management Limited
2.35%
Susquehanna International Group, LLP
0.82%
Schonfeld Strategic Advisors LLC
0.79%
Acadian Asset Management LLC
0.75%
Other
91.78%
股东类型
股东统计
占比
Venture Capital
5.86%
Investment Advisor
2.08%
Hedge Fund
1.60%
Research Firm
1.12%
Investment Advisor/Hedge Fund
0.78%
Individual Investor
0.22%
Other
88.33%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
50
678.81K
11.95%
+387.28K
2024Q4
52
469.91K
11.91%
+42.72K
2024Q3
52
279.81K
7.09%
-247.00K
2024Q2
51
362.89K
15.79%
-1.48K
2024Q1
59
340.51K
14.80%
-343.96K
2023Q4
65
549.25K
25.71%
-320.80K
2023Q3
68
668.24K
31.65%
-112.66K
2023Q2
71
571.34K
27.26%
-362.30K
2023Q1
81
667.89K
31.87%
-504.63K
2022Q4
87
672.60K
32.11%
-559.71K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Sofinnova Investments, Inc
199.52K
3.51%
+199.52K
--
Feb 14, 2025
Abingworth Management Limited
133.33K
2.35%
--
--
Dec 31, 2024
Susquehanna International Group, LLP
46.72K
0.82%
+46.72K
--
Dec 31, 2024
Schonfeld Strategic Advisors LLC
45.07K
0.79%
+45.07K
--
Dec 31, 2024
Acadian Asset Management LLC
42.41K
0.75%
+18.79K
+79.54%
Dec 31, 2024
Virtu Americas LLC
40.40K
0.71%
+40.40K
--
Dec 31, 2024
Baillie Gifford & Co.
36.70K
0.65%
--
--
Dec 31, 2024
Citadel Advisors LLC
25.00K
0.44%
+25.00K
--
Dec 31, 2024
Two Sigma Investments, LP
20.99K
0.37%
+20.99K
--
Dec 31, 2024
Glass Jacobson Wealth Advisors
15.00K
0.26%
--
--
Dec 31, 2024
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
公告日期
类型
比率
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1
Apr 12, 2024
Merger
25<1